WO2003047593A1 - Inhibiteurs de melanogenese et agents blanchissants renfermant des derives d'ergosterol, et compositions contenant ces derives - Google Patents

Inhibiteurs de melanogenese et agents blanchissants renfermant des derives d'ergosterol, et compositions contenant ces derives Download PDF

Info

Publication number
WO2003047593A1
WO2003047593A1 PCT/JP2002/012647 JP0212647W WO03047593A1 WO 2003047593 A1 WO2003047593 A1 WO 2003047593A1 JP 0212647 W JP0212647 W JP 0212647W WO 03047593 A1 WO03047593 A1 WO 03047593A1
Authority
WO
WIPO (PCT)
Prior art keywords
whitening
ergosterol
melanin production
ergosterol derivative
extract
Prior art date
Application number
PCT/JP2002/012647
Other languages
English (en)
Japanese (ja)
Inventor
Kenji Sakamoto
Original Assignee
Sakamoto Bio Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sakamoto Bio Co., Ltd. filed Critical Sakamoto Bio Co., Ltd.
Priority to JP2003548848A priority Critical patent/JPWO2003047593A1/ja
Priority to KR10-2004-7008661A priority patent/KR20040073459A/ko
Priority to AU2002354353A priority patent/AU2002354353A1/en
Publication of WO2003047593A1 publication Critical patent/WO2003047593A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Definitions

  • the present invention relates to a melanin production inhibitor and a whitening agent comprising an ergosterol derivative, and a composition containing the ergosterol derivative, particularly a cosmetic, a medicine, a skin external preparation, and a food. More specifically, to suppress the production of melanin in melanocytes, to prevent, improve and treat whitening of tanned skin after UV irradiation, and to prevent pigmentation of skin such as spots, freckles, and plaques due to sunburn.
  • the present invention relates to a melanin production inhibitor and a whitening agent, and a composition, particularly a cosmetic, a medicine, a skin external preparation, and a food. Background art
  • Pigmentation of skin such as spots, freckles, and plaques due to sunburn, etc., occurs with aging and increases with age or becomes difficult to disappear, which is a problem for middle-aged and elderly people. .
  • melanin is produced in melanin-producing granules called melanosomes in melanosite in epidermal cells due to sunburn (especially ultraviolet rays) due to sunburn. It is thought to be caused by the diffusion of the produced melanin pigment to neighboring cells.
  • L-ascorbic acid has a poor stability, and kojic acid has a certain effect, but its effect is weak.
  • hide mouth Quinones have also been shown to be effective, but they have irritation and allergic properties, have safety issues, and have problems with their formulation as a drug. Therefore, at present, a substance having a sufficient effect of preventing and improving pigmentation has not yet been known.
  • the compound according to the present invention is a known substance, it has an effect of suppressing melanin production and is not known to have a skin lightening effect (for example, Koita Ohta, Yasunori Yaoi ta). and Masao Kikuchi), Natural Medicines (Natural Medicines) (cited book), 1996, Vol. 50, No. 5, p.
  • the present invention has been made in view of the above circumstances, and its purpose is to whiten tanned skin after irradiation with ultraviolet light, and to prevent, improve, and treat skin pigmentation such as spots, freckles, and spots due to sunburn. And a composition containing the same. Disclosure of the invention
  • the present inventors have conducted intensive studies in order to solve the above problems, and as a result, have found that an ergosterol derivative having a specific structure has a strong melanin production inhibitory action and a whitening effect, and the above problems can be solved.
  • the invention has been completed.
  • the present invention is a melanin production inhibitor and a whitening agent containing the ergosterol derivative represented by the formula (1).
  • the present invention is a composition for suppressing melanin production and a composition for whitening, comprising the ergosterol derivative represented by the formula (1).
  • the present invention is a cosmetic containing the ergosterol derivative represented by the formula (1), and this cosmetic can be used for inhibiting melanin production and whitening.
  • the present invention is a medicine containing the ergosterol derivative represented by the above formula (1), and this medicine can be used for inhibiting melanin production and for whitening.
  • the present invention is also an external preparation for skin containing the ergosterol derivative represented by the formula (1), and this external preparation for skin can be used for suppressing melanin production and whitening.
  • the present invention is a food for suppressing melanin production and a food for whitening, which contains the ergosterol derivative represented by the formula (1).
  • a composition for inhibiting melanin production a composition for whitening, a cosmetic for inhibiting melanin production, a skin-whitening or the like, and a melanin production inhibitor, comprising the ergosterol derivative represented by the formula (1).
  • a composition such as a medicinal product for whitening, whitening and the like, a skin external preparation for suppressing melanin production and whitening, a food for suppressing melanin production, and a food for whitening.
  • the whitening agent component may further be contained.
  • the combination use of the whitening agent component and the ergosterol derivative represented by the above formula (1) can synergistically improve the melanin production inhibitory effect and the whitening effect.
  • the ergosterol derivative (hereinafter, simply referred to as ergosterol derivative) is a known substance and can be isolated from fungi, for example. Although any fungi containing the ergosterol derivative can be used for the production of the ergosterol derivative, it is convenient to use, for example, chlorophyll lum molybdites. It can also be prepared by chemical synthesis.
  • the ergosterol derivative can be isolated from fungi containing the ergosterol derivative as follows.
  • the fungal fruit body, or the mycelium, spores, etc. are preferably partially ground, and then immersed in an extraction solvent or heated to reflux in the extraction solvent, and then insoluble matter is removed by filtration, centrifugation, or the like.
  • the extract solution obtained by the removal is optionally concentrated, and then isolated by a known separation and purification means.
  • the solvent used for the extraction may be a solvent usually used for the extraction of fungi, plants and the like.
  • alcohols such as methanol and ethanol
  • organic solvents such as acetate and ethyl acetate
  • water are used alone or in combination. be able to.
  • the extraction method may be a conventional method.
  • the extraction temperature is in the range of 0 to 100 ° C, preferably 40 to 70 ° C
  • the extraction time is 1 to 168 ° C. Hours, preferably 24 to 72 hours.
  • Isolation from the extraction solution can be performed, for example, by chromatography such as reverse phase chromatography, gel filtration column chromatography, or liquid chromatography. This can be done by torography.
  • the ergosterol derivative of the present invention has a melanin production inhibitory action and a whitening action as described below. Therefore, it can be used as a melanin production inhibitor and a whitening agent. Further, it can be applied to a melanin production inhibitor and a whitening agent containing an ergosterol derivative.
  • These melanin production inhibitors and whitening agents suppress melanin production at melanosites and prevent whitening of tanned skin after UV irradiation, and prevent pigmentation of skin such as spots, freckles, and plaques due to sunburn. Can be improved and treated.
  • the composition contains an ergosterol derivative, a composition for inhibiting melanin production and a whitening composition, and further contains an ergosterol derivative, various cosmetics in the cosmetics, pharmaceuticals, and food fields, pharmaceuticals, and skin. It can be applied to external preparations, foods for suppressing melanin production, foods for whitening, and the like.
  • the cosmetics, medicaments, and external preparations for skin are preferably applied for suppressing the production of melaene having the function of the ergosterol derivative and for whitening.
  • the composition is a composition for preventing and treating the symptoms related to the suppression of melanin production and whitening.
  • composition of the present invention can be in both oral (internal) or parenteral (external) form.
  • oral use the composition of the present invention can be prepared in the form of, for example, a medicine or food.
  • parenteral use it may be in the form of cosmetics, quasi-drugs, pharmaceuticals, skin external preparations Can be prepared.
  • the ergosterol derivative When the ergosterol derivative is incorporated into the composition of the present invention, a pure product of the ergosterol derivative is incorporated, and the ergosterol derivative is extracted in the form of an extract or an extract of a plant or fungus containing the ergosterol derivative. No problem.
  • the composition containing the ergosterol derivative that is, a composition for inhibiting melanin production, a composition for whitening, a cosmetic for inhibiting melanin production and whitening, and a medicine for inhibiting melanin production and whitening.
  • Compositions such as skin external preparations for inhibiting melanin production and whitening, foods for inhibiting melanin production, and foods for whitening include, in addition, whitening ingredients other than the ergosterol derivative (hereinafter simply referred to as whitening ingredients).
  • whitening ingredients other than the ergosterol derivative
  • the combination use of the ergosterol derivative and the whitening agent component can synergistically improve the melanin production inhibitory effect and the whitening effect.
  • the whitening agent component is not particularly limited and includes, for example, ascorbic acid and its derivatives and salts thereof (eg, ascorbic acid, ascorbic acid 2-darcoside, magnesium ascorbic acid phosphate ester, ascorbic acid) Sodium, ascorbyl stearate, ascorbyl palmitate, ascorbyl dipalmitate, tetriso ascorbyl palmitate, magnesium ascorbate, chitosanas conorelate, asconorevinole methinolesyl lactone , Ascorbic acid polypeptide, diazerine asconolevinolate, asconolelevic acid polyester ester / res, ascorbyl acid polyoxyethylene derivative, ascorbyl ricinoleate, ascorbyl acid 12-sulfate Sternadium salt, etc.), idroquinone and its derivatives and their salts (eg, arbutin), cystine and its derivatives, and their salts (eg, L-c
  • One or more kinds of whitening agents can be arbitrarily selected and blended.
  • the amount (content) of the whitening agent component is preferably 0.001 to: 0% by weight of the total amount of the composition, and more preferably 0.1% by weight.
  • compositions of the present invention containing an ergosterol derivative will be described in more detail according to their uses.
  • Cosmetics which are the first use of the present invention include, for example, ointments, solutions, creams, emulsions, lotions, lotions, jewels, essences (essences), foundations, pack masks, lipsticks, Stick, c also is applicable in a wide range including quasi-drugs as a skin external preparation such as bath salts, cosmetic dosage form also, solution system, solubilized system, emulsified system, powder-based, powder
  • a wide range of dosage forms such as powder dispersion, oil-liquid, gel, ointment, aerosol, water-oil-two-layer system, water-oil-powder three-layer system can be adopted.
  • the amount of the ergosterol derivative to be added to the cosmetic of the present invention is preferably from 0.001 to 20% by weight, more preferably from 0.01 to 16% by weight, even more preferably from 0 to 16% by weight based on the total amount of the cosmetic. It is 1 to 12% by weight. Most preferred is 1 to 10% by weight.
  • the cosmetic of the present invention is characterized in that Since it has an inhibitory action and a whitening action, it is used as a melanin production inhibiting cosmetic and a whitening cosmetic.
  • the cosmetic of the present invention can be preferably used particularly as an external preparation for skin, and is used as a skin external preparation for suppressing melanin production and a skin external preparation for whitening.
  • the medicament which is the second use of the present invention can be administered by oral administration or parenteral administration, and can be in the form of a pharmaceutical preparation suitable for each.
  • Pharmaceutical preparations include, for example, liquid preparations such as liquid preparations, syrup preparations, injection preparations, inhalation preparations and emulsions, solid preparations such as tablets, powders, granules, capsules, inhalation preparations, external preparations such as ointments, and the like. External preparations such as suppositories and the like can be mentioned.
  • the amount of the ergosterol derivative in the pharmaceutical preparation is in the total amount of the pharmaceutical preparation
  • the dose will vary as appropriate based on the age and weight of the patient, the route of application, the degree of disease progression and concurrent treatment, and will not be specified, but generally It can be administered at a dose of about 4 to 1 Oml per day, once or twice or three times a day, but is not limited thereto. Since the medicament of the present invention has a melanin production inhibitory action and a whitening action, it is used as a melanin production inhibitory medicine and a whitening medicine. In addition, the medicament of the present invention can be preferably applied particularly to the use as an external preparation for skin, and thus is used as an external preparation for skin for suppressing melanin production and an external preparation for skin whitening.
  • the food which is the third application of the present invention, is useful as a so-called health functional food, and is widely applied, for example, as confectionery, beverages such as soft drinks, processed vegetables or fruits, livestock meat products, seasonings, and the like. It is possible. Its form is powder, solid product, solution, etc. The amount of the ergosterol derivative in the food can be appropriately changed depending on the purpose, product form, and the like. Generally, in the case of a solution such as a drink, for example,
  • the amount is, for example, 0.0001 to 10 mg, preferably 0.01 to 5 mg, and more preferably 0.0 to! Since the food of the present invention has a melanin production inhibitory action and a whitening action, it is used as a melanin production inhibitory food and a whitening food.
  • composition of the present invention for cosmetics, medicines, foods and the like includes, in addition to the above-mentioned ergosterol derivatives as long as the effects of the present invention are not impaired, other compositions commonly used in cosmetics, medicines, external preparations for skin, foods and the like.
  • the following components can be blended.
  • cosmetics include oils, powders, surfactants, humectants, thickeners, lower alcohols, film agents, UV absorbers, sequestering agents, organic amines, PH regulators, medicinal ingredients, sugars, Examples include preservatives, vitamins, antioxidants, fragrances, water and the like.
  • oils examples include natural oils such as jojoba oil, olive oil, apogado oil, castor oil, coconut oil, tallow, hydrogenated oil, liquid lanolin, and derivatives thereof, waxes such as carnauba wax, beeswax, and lanolin.
  • Liquid paraffin Liquid paraffin, hydrocarbons such as microcrystalline wax, squalane and petrolatum, higher fatty acids such as stearic acid, higher alcohols such as cetyl alcohol and stearyl alcohol, glycerin monostearate, Glyceryl trioctanoate, glycerin monoolate, isopropylyl myristate, diisostearyl lingoate, glycerin di-2-heptinoledenedecanoate, trimethylolprononyl tri-2-ethynolehexenolate, Trimethylol trioctanoate propane, di 2-ethyl sepate Estenoles such as Norehexinole, essential oils such as rose oil, rose oil, citronella nore, and silicone oils such as Dimethinolepolysiloxane and decamethylcyclopentapentasiloxane.
  • the amount of the oil content in the cosmetic is appropriately selected according to the form
  • Examples of powders include talc, my strength, kaolin, silica, zinc white, Examples include titanium mica, titanium oxide, iron oxide, and nylon powder.
  • Examples of the surfactant include polyoxyethylene alkyl ether, polyoxyethylene fatty acid ester, polyoxyethylene sorbitan fatty acid ester, glycerin fatty acid ester, polyoxyethylene hardened castor oil, and polyoxyethylene.
  • Nonionic surfactants such as sorbitol fatty acid esters and polyoxyalkylene-modified polysiloxanes.
  • Anionic surfactants such as sodium palmitate; cationic surfactants such as stearyl chloride and trimethylammonium; betaines and amidobetaines.
  • amphoteric surfactants such as sulfobetaine and imidazolyem.
  • humectants examples include glycerin, 1,3-butylene glycol, polyethylene glycolone, dipropylene glycolone, and sonorebitone.
  • thickener examples include water-soluble polymers such as carboxybutyl polymer, carboxymethylcellulose, and polyvinyl alcohol, and clay minerals such as bentonite.
  • UV absorbers examples include para-aminobenzoic acid (hereinafter abbreviated as PABA), glyceryl PABA, ethyldihydroxypropyl PABA, octylmethoxycinnamate, 2-ethoxyhexyl-p-methoxycinnamate, and 2,4-dihydroxybenzophene.
  • PABA para-aminobenzoic acid
  • glyceryl PABA glyceryl PABA
  • ethyldihydroxypropyl PABA ethyldihydroxypropyl PABA
  • octylmethoxycinnamate 2-ethoxyhexyl-p-methoxycinnamate
  • 2,4-dihydroxybenzophene examples include para-aminobenzoic acid (hereinafter abbreviated as PABA), glyceryl PABA, ethyldihydroxypropyl PABA, octylmethoxycinnamate,
  • Examples of sequestering agents include tetrasodium edetate, citric acid and the like.
  • lower alcohols include ethanol.
  • Examples of organic amines include monoethanolamine, triethanolamine and the like.
  • Examples of pH regulators include: Buffers such as sodium lactate-lactate and sodium citrate-monoatenoate are exemplified.
  • Examples of the medicinal component include pantothenyleethyl ether, glycyrrhizinate and the like.
  • Examples of vitamins include vitamin E or derivatives thereof.
  • Examples of antioxidants include tocopherones, djibuti hydroxytonolene, and propynole gallate.
  • sugars include erythritol, sucrose, hyaluronic acid and the like.
  • preservatives include ethyl paraben, butyl paraben, sodium benzoate and the like.
  • it can be selected from components that can be added to the below-mentioned medicines and foods and can be added.
  • additives such as excipients, stabilizers, wetting agents, emulsifiers, absorption enhancers, pH adjusters, surfactants, diluents, carriers and the like
  • additive components include starch, sugars such as lactose, magnesium sulfate, talc, gelatin, senorolose derivatives such as hydroxypropyl / resenololose, vegetable oils such as soybean oil and sesame oil, and the like.
  • examples thereof include water such as animal oil or synthetic oil, rubber, physiological saline and the like, and alcohols such as ethanol, 1,3-butylene glycol, polyalkylene dalicol and the like.
  • it can be selected from the above-mentioned cosmetics and components that can be added to the foods described below, and can be added.
  • foods include sweeteners, acidulants, preservatives, flavors, coloring agents, excipients, stabilizers, wetting agents, emulsifiers, absorption enhancers, pH adjusters, surfactants, diluents, carriers And other various additional components.
  • additional components include mushroom extract, ginseng extract, ginger extract, various food extract extracts such as honey, liquid food, and sugars such as cyclic oligosaccharide, reduced maltose, and sugar.
  • Rehalose, lactose, sucrose fatty acid esters and the like can be mentioned.
  • it can also be selected from the ingredients that can be blended with the cosmetics and medicaments and blended.
  • composition of the present invention can be prepared into any form and dosage form by a conventional method by mixing the essential component of the present invention and one or more of the above optional components.
  • the present invention will be described specifically with reference to examples.
  • the compounding amount of the composition those not particularly described are% by weight.
  • B1610F7 melanoma cells obtained from Akita Prefectural Food Research Institute
  • a solution obtained by diluting the ergosterol derivative purified in the above purification example with a culture solution is applied to the cells to produce melanin.
  • B-16 cells wash 70% confluent cells with PBS, add trypsin and detach, and add the same amount of serum-containing medium (E
  • the ergosterol derivative solution was diluted by dispensing 20 ii L of sterile PBS into a cell culture plate (for adherent cells), taking 20 ⁇ L of the ergosterol derivative solution, and diluting it twice (final concentration in the culture solution). 1 OO ⁇ a gZmL O. OOl S ⁇ g / mL).
  • Arbutin as a con preparative roll final concentration 1 4 0 ⁇ 8 / ⁇ ⁇ 0. 2 2 U gZmL in culture
  • methanol was also diluted similarly.
  • the ergosterol derivative has a melanin generation inhibitory effect (whitening effect) on melanoma B16 cells, which is comparable to that of arbutin, a melanin generation inhibitor. Obviously, it is useful as an agent.
  • the micrograph of the ergosterol derivative shows that the blackness of B-16 cells is suppressed to the same extent as that of arbutin, confirming that it has an excellent melanin production inhibitory effect and a whitening effect. Was done.
  • Test compound (listed in Table 2) Amount described in Table 2
  • Test compound Effect Example 2 0.2 ⁇
  • Example 3 Ergosterone monoleate derivative 1.0 ⁇ Comparative example 1 Unadded calo X Comparative example 2
  • the composition (lotion) containing the ergosterol derivative prevented the deposition of melanin pigment, inhibited melanin production, and exhibited a whitening effect.
  • no test compound was added (Comparative Example 1) and when hydroquinone was added (Comparative Example 2), no effect was observed.
  • Table 3 shows the names and amounts of the whitening agents used together with the ergosterol derivative.
  • Table 4 shows the results. Table 4 shows the number of persons who correspond to each judgment item by judgment. Table 4
  • Vitamin E 0.05 sodium sodium sulfite
  • PEG 150 0 5 0 5 Carboxyvinyl polymer 10 0 Lioxyethylene (50 mol) oleyl ether 20 Hydroxium hydroxide 0 1 5 Ergosteal derivative 0 Ascorbic acid 2-gunolecoside 0 0 1
  • Blended amount (% by weight) Polyvinyl acetic anhydride 1 50 Polyvinyl oleanol 1 0 0 Dipropylene glycol 50 0 Sorbitol 5 0 Tocoyl acetate 0 2 Olive oil 1 0 Screen 3 0 E. Lioxyethylene (20 mol) solhi, tanmonoolein ⁇ ester 5 Titanium oxide 50 0 Talc 100 Ethanore 70 Enolegosterone derivative 30 Preservative
  • Bentonite 0 5 e. Lioxyethylene (20 mol) solhi, tanmonostearate 10 Triethanolamine 0 Glycerin 50 Propylene glycol 50 Stearic acid 20 Glycerin monostearate 100 Liquid paraffin 100 Dimethyl polysiloxane 50 Polyoxyalkylene-modified polysiloxane xanose 30 water
  • a novel melanin production inhibitor, a whitening agent, and a composition having a melanin production inhibitory action and a whitening action can be obtained.
  • it has a melanin production inhibitory effect and a whitening effect, and has an excellent effect on whitening of tanned skin after UV irradiation, and prevention, improvement and treatment of skin pigmentation such as spots, freckles and melasma due to sunburn.
  • the composition of the present invention can synergistically improve the melanin production-suppressing effect and the whitening effect by blending the ergosterol derivative together with a whitening component.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Birds (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des substances efficaces pour blanchir la peau brûlée par le soleil après une irradiation par rayonnement ultraviolet, et pour prévenir, atténuer et traiter la pigmentation de la peau (par exemple, taches dues aux coups de soleil ou autres, taches de rousseur et taches de vieillesse). L'invention concerne également des compositions renfermant ces substances. Pour les besoins de l'invention, on utilise des inhibiteurs de mélanogenèse et des agents blanchissants qui contiennent des dérivés d'ergostérol; des inhibiteurs de mélanogenèse et des agents blanchissants qui contiennent ces dérivés; des compositions inhibant la mélanogenèse et des compositions blanchissantes qui contiennent les dérivés en question; des cosmétiques, des médicaments, des préparations à usage externe pour la peau, des aliments inhibiteurs de mélanogenèse et des aliments blanchissants qui contiennent les dérivés considérés; et enfin ces compositions, cosmétiques, médicaments, préparations à usage externe pour la peau, aliments inhibiteurs de mélanogenèse et aliments blanchissants qui contiennent les dérivés susmentionnés, en combinaison avec un ou plusieurs agents blanchissants autres que lesdits dérivés. On dispose ainsi d'inhibiteurs de mélanogenèse, d'agents blanchissants et de compositions à effet inhibiteur de mélanogenèse et effet blanchissant (par exemple, cosmétiques, médicaments, préparations à usage externe pour la peau et aliments).
PCT/JP2002/012647 2001-12-05 2002-12-03 Inhibiteurs de melanogenese et agents blanchissants renfermant des derives d'ergosterol, et compositions contenant ces derives WO2003047593A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2003548848A JPWO2003047593A1 (ja) 2001-12-05 2002-12-03 エルゴステロール誘導体からなるメラニン生成抑制剤及び美白剤、並びにエルゴステロール誘導体を含有する組成物
KR10-2004-7008661A KR20040073459A (ko) 2001-12-05 2002-12-03 에르고스테롤 유도체로 이루어지는 멜라닌 생성억제제 및미백제 그리고 에르고스테롤 유도체를 함유하는 조성물
AU2002354353A AU2002354353A1 (en) 2001-12-05 2002-12-03 Melanogenesis inhibitors and whitening agents comprising ergosterol derivatives and compositions containing ergosterol derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-370989 2001-12-05
JP2001370989 2001-12-05

Publications (1)

Publication Number Publication Date
WO2003047593A1 true WO2003047593A1 (fr) 2003-06-12

Family

ID=19180115

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/012647 WO2003047593A1 (fr) 2001-12-05 2002-12-03 Inhibiteurs de melanogenese et agents blanchissants renfermant des derives d'ergosterol, et compositions contenant ces derives

Country Status (5)

Country Link
JP (1) JPWO2003047593A1 (fr)
KR (1) KR20040073459A (fr)
CN (1) CN1311834C (fr)
AU (1) AU2002354353A1 (fr)
WO (1) WO2003047593A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006182731A (ja) * 2004-12-28 2006-07-13 Ichimaru Pharcos Co Ltd 化粧料組成物又は飲食品
JP2022073954A (ja) * 2020-10-30 2022-05-17 ジーエムイーエックス（グローバル メディカル シナプス） カルベジロールを有効成分として含む皮膚美白用組成物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103845234A (zh) * 2014-02-13 2014-06-11 上海珍馨化工科技有限公司 透明质酸美白霜

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58113118A (ja) * 1981-12-26 1983-07-05 Nonogawa Shoji:Kk 化粧料
JPH0249710A (ja) * 1988-05-20 1990-02-20 Narisu Keshohin:Kk 化粧料
JPH07316035A (ja) * 1994-03-31 1995-12-05 Usuki Seiyaku Kk 皮膚外用剤
EP0738510A2 (fr) * 1995-04-20 1996-10-23 L'oreal Utilisation d'un inhibiteur d'hmg coenzyme A reductase pour lutter contre le vieillissement de la peau
JPH11199499A (ja) * 1998-01-07 1999-07-27 Kanebo Ltd 脂肪合成促進剤および豊胸用皮膚外用組成物
JP2000319191A (ja) * 1999-03-05 2000-11-21 Takeda Chem Ind Ltd サイクリックｇｍｐ特異的ホスホジエステラーゼ阻害剤および性的機能障害改善薬
WO2002030366A1 (fr) * 2000-10-11 2002-04-18 Sakamoto Bio Co., Ltd. Inhibiteurs de la melanogenese et azurants renfermant un derive d'ergosterol et compositions renfermant ce derive

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58113118A (ja) * 1981-12-26 1983-07-05 Nonogawa Shoji:Kk 化粧料
JPH0249710A (ja) * 1988-05-20 1990-02-20 Narisu Keshohin:Kk 化粧料
JPH07316035A (ja) * 1994-03-31 1995-12-05 Usuki Seiyaku Kk 皮膚外用剤
EP0738510A2 (fr) * 1995-04-20 1996-10-23 L'oreal Utilisation d'un inhibiteur d'hmg coenzyme A reductase pour lutter contre le vieillissement de la peau
JPH11199499A (ja) * 1998-01-07 1999-07-27 Kanebo Ltd 脂肪合成促進剤および豊胸用皮膚外用組成物
JP2000319191A (ja) * 1999-03-05 2000-11-21 Takeda Chem Ind Ltd サイクリックｇｍｐ特異的ホスホジエステラーゼ阻害剤および性的機能障害改善薬
WO2002030366A1 (fr) * 2000-10-11 2002-04-18 Sakamoto Bio Co., Ltd. Inhibiteurs de la melanogenese et azurants renfermant un derive d'ergosterol et compositions renfermant ce derive

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GUYOT ET AL., BIOMEDICINE & PHARMACOTHERAPY, vol. 40, no. 5, 1986, pages 195 - 197, XP002965859 *
KEISHI HATA ET AL., NATURAL MEDICINES, vol. 55, no. 6, 2001, pages 304 - 307, XP002965256 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006182731A (ja) * 2004-12-28 2006-07-13 Ichimaru Pharcos Co Ltd 化粧料組成物又は飲食品
JP2022073954A (ja) * 2020-10-30 2022-05-17 ジーエムイーエックス（グローバル メディカル シナプス） カルベジロールを有効成分として含む皮膚美白用組成物

Also Published As

Publication number Publication date
CN1311834C (zh) 2007-04-25
CN1615138A (zh) 2005-05-11
KR20040073459A (ko) 2004-08-19
JPWO2003047593A1 (ja) 2005-04-14
AU2002354353A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
JP5683134B2 (ja) 皮膚外用剤
JP2003300860A (ja) 皮膚外用剤
JP2011246353A5 (fr)
JP2004131431A (ja) 紫外線傷害予防又は改善用組成物
KR102024628B1 (ko) 발아콩 추출물을 포함하는 미백용 또는 탈모 방지용 조성물
JPH10139679A (ja) ケミカルメディエーター遊離抑制剤及びこれを含有する化粧料，医薬品並びに食品
JP4115656B2 (ja) エルゴステロール誘導体からなるメラニン生成抑制剤及び美白剤
KR101112006B1 (ko) 멜라닌 생성 촉진제 및 멜라닌 생성 촉진용 조성물
JP5124280B2 (ja) 苦甘草（ＳｏｐｈｏｒａＡｌｏｐｅｃｕｒｏｉｄｅｓＬ．）抽出物を含有する化粧品組成物
JP2007277120A (ja) マンネンタケ抽出物の抽出方法及び該マンネンタケ抽出物を含有する美白剤
JP4226228B2 (ja) ガノデロールｂからなるメラニン生成抑制剤及び美白剤、並びにガノデロールｂを含有する組成物
WO2003047593A1 (fr) Inhibiteurs de melanogenese et agents blanchissants renfermant des derives d'ergosterol, et compositions contenant ces derives
JP4632115B2 (ja) エゴノール誘導体からなるメラニン生成抑制剤及び美白剤、並びにエゴノール誘導体を含有する組成物
JP4076477B2 (ja) 皮膚外用剤
JPH10120546A (ja) 美白用皮膚外用剤
KR102155246B1 (ko) 황칠나무 추출물-금속염 나노입자 복합체를 포함하는 피부상태 개선용 조성물
WO2004028484A1 (fr) Agents de demelanisation, agents d'embellissement, compositions de demelanisation et compositions d'embellissement
KR101704922B1 (ko) 4-하이드록시사타바신을 포함하는 조성물
JP3980986B2 (ja) メラノサイトのデンドライト伸長抑制剤及びそれを含有する皮膚外用剤
JP2003267873A (ja) エルゴステロール誘導体からなるメラニン生成抑制剤及び美白剤、並びにエルゴステロール誘導体を含有する組成物
JPWO2004089393A1 (ja) 光老化防御剤、光老化改善剤、コラゲナーゼ阻害剤及びチロシナーゼ阻害剤
JP2003095969A (ja) ヒスタミンｈ２受容体拮抗剤
JP2004075558A (ja) 美白改善用キット
WO2003082227A1 (fr) Régulateur de mélanogenèse
KR20170099699A (ko) 디메톡시커큐민을 포함하는 피부 상태 개선용 조성물

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1020047008661

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20028273133

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2003548848

Country of ref document: JP

122 Ep: pct application non-entry in european phase